We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$475M
AUM Growth
+$226M
Cap. Flow
+$193M
Cap. Flow %
40.57%
Top 10 Hldgs %
41.72%
Holding
154
New
62
Increased
25
Reduced
13
Closed
48

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$7.96M
2
AMGN icon
Amgen
AMGN
+$5.99M
3
AZTA icon
Azenta
AZTA
+$5.35M
4
ESTA icon
Establishment Labs
ESTA
+$5.33M
5
CNC icon
Centene
CNC
+$5.26M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$3.59M
2
HOLX
Hologic
HOLX
+$3.48M
3
ATHN
Athenahealth, Inc.
ATHN
+$3.34M
4
AGN
Allergan plc
AGN
+$3.33M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 35.48%
2 Industrials 0.59%
3 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
126
CALL
STAAR Surgical
STAA
$1.24B
– –
-17,500
Closed -$543K
TGTX icon
127
TG Therapeutics
TGTX
$7.64B
– –
-50,000
Closed -$658K
VKTX icon
128
Viking Therapeutics
VKTX
$3.94B
– –
-47,100
Closed -$447K
VKTX icon
129
PUT
Viking Therapeutics
VKTX
$3.94B
– –
-100,000
Closed -$949K
VRTX icon
130
Vertex Pharmaceuticals
VRTX
$134B
– –
-15,000
Closed -$2.55M
XENE icon
131
Xenon Pharmaceuticals
XENE
$6.11B
– –
-75,000
Closed -$690K
XNCR icon
132
Xencor
XNCR
$1.64B
– –
-15,000
Closed -$555K
ZVRA icon
133
Zevra Therapeutics
ZVRA
$673M
– –
-3,750
Closed -$390K
TECX
134
Tectonic Therapeutic
TECX
$623M
– –
-4,375
Closed -$1.5M
TVRD
135
CALL
Tvardi Therapeutics
TVRD
$22.1M
– –
-2,778
Closed -$1.92M
ITCI
136
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-20,000
Closed -$418K
TTOO
137
DELISTED
T2 Biosystems, Inc
TTOO
– –
-30
Closed -$1.16M
MOTS
138
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
– –
-333
Closed -$719K
SIEN
139
CALL
DELISTED
Sientra, Inc.
SIEN
– –
-12,540
Closed -$2.45M
SIEN
140
DELISTED
Sientra, Inc.
SIEN
– –
-18,390
Closed -$3.59M
SYNH
141
CALL
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-60,000
Closed -$2.81M
SPPI
142
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-130,700
Closed -$2.74M
CSII
143
CALL
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-58,000
Closed -$1.88M
GBT
144
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-10,300
Closed -$466K
GBT
145
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-50,000
Closed -$2.26M
XENT
146
PUT
DELISTED
Intersect ENT, Inc
XENT
– –
-70,000
Closed -$2.62M
GWPH
147
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-30,000
Closed -$4.19M
IMMU
148
DELISTED
Immunomedics Inc
IMMU
– –
-50,400
Closed -$1.19M
AKRX
149
CALL
DELISTED
Akorn Inc
AKRX
– –
-67,900
Closed -$1.13M
AGN
150
DELISTED
Allergan plc
AGN
– –
-20,000
Closed -$3.33M
3 4 5
6
7

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Pura Vida Investments held 154 positions worth $475M, up 91% from $250M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Pura Vida Investments deployed $193M of net new capital in Q3 2018, opening 62 new positions and adding to 25 existing holdings. Its largest new stake was Amgen: 30,373 shares worth $6.3M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $2.36M trimmed.

  • Pura Vida Investments's largest Q3 2018 buy was Amgen: 30,373 shares worth $6.3M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2018, an estimated $7.96M increase.
  • Pura Vida Investments's biggest Q3 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $2.36M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2018, selling an estimated $3.59M.
  • Pura Vida Investments's ten largest holdings make up 42% of its $475M portfolio in Q3 2018.
  • Pura Vida Investments opened 62 new positions and closed 48 in Q3 2018.
  • Pura Vida Investments's portfolio value rose 91% quarter-over-quarter to $475M.

Based on Pura Vida Investments's 13F filing for Q3 2018, filed 14 Nov 2018.